The quest to modernize ADHD diagnosis just got a $1.9M boost, as Evolve Neuro announced its seed funding round. The company is tackling a global market underserved by outdated, subjective methods, leveraging proprietary neuroscience and AI to transform how ADHD is identified.
Evolve Neuro's core offering is a 10-minute EEG-based assessment designed to unlock scalable, evidence-backed insights. This capital will support their mission to bring more objective, data-driven tools to a critical area of mental health.
